KYNB

#4538
Kyntra Bio, Inc. Common Stock
7.37 USD
+4.10%
Sector:
Básica: USD
Divisa de beneficio: USD
Rango diario
7.37
7.37
Rango anual
6.32
9.70
Cambio diario
+4.10%
Variación mensual
+3.08%
Variación en los últimos 6 meses
-22.50%
Cambio anual
-22.50%
Cierres anteriores
7.08
Abrir
7.37
Bid
Ask
Mínimo
7.37
High
7.37
Volumen
2
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
Informe de resultados Saldo Flujo de caja
Valor 202020212022202320242025 TTM

Kyntra Bio Inc

Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate. On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB.